By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – ACS Biomarker reported on Friday it has closed on a financing round and appointed a new CEO.

The amount of the funding was not disclosed. In a statement, the company, based in Maastricht, Netherlands, said it will be used to further develop its product pipeline and discover novel biomarkers "that improve diagnosis, prognosis, and management of cardiac diseases."

Funding came from Life Sciences Fund Amsterdam and Limburg Ventures, ACS said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.